8-K: BioXcel's BXCL501 Phase 3 Home-Use Agitation Study

BioXcel Therapeutics announced positive safety and efficacy signals from its Phase 3 study of BXCL501 for agitation in bipolar disorder and schizophrenia in the home setting.

Summary

• BioXcel Therapeutics presented Phase 3 study results for BXCL501 (sublingual dexmedetomidine) for the treatment of agitation associated with bipolar disorder or schizophrenia in the home setting.
• The study, SERENITY At-home (NCT05658510), was a randomized, double-blind, placebo-controlled, 12-week trial primarily focused on safety and tolerability.
• The trial included 246 randomized patients, with 208 patients treating a total of 2437 agitation episodes.
• 81% of treated patients successfully completed the 12-week study period.
• Adverse event frequencies with a single dose of BXCL501 were similar to those observed in previous Phase 3 studies conducted under medical supervision.
• No increase in the incidence of adverse events was observed over repeated administrations of BXCL501.
• No patient in the active treatment arm discontinued the study due to treatment-emergent adverse events (TEAEs).
• Although not powered for efficacy, the reduction in modified Clinical Global Impression Severity (mCGI-S) score was significantly greater in the active group compared with placebo (P<0.05).
• A mean reduction in mCGI-S score of 1.2 was observed following the first 12 doses, and a mean reduction of 1.4 was seen following 13 or more doses, indicating no attenuation of benefit with repeat dosing.
• Complete resolution of agitation was significantly higher with BXCL501 compared to placebo across all agitation episode severities (P<.0001).

Sentiment

Score: 8

Explanation: The filing reports positive safety and tolerability results for BXCL501 in a Phase 3 home-use study, meeting its primary safety endpoint. Additionally, strong exploratory efficacy signals were observed, indicating a significant unmet need could be addressed. This is a strong positive for the company's pipeline and potential market expansion.

Positives

• BXCL501 was safe and well tolerated over a 12-week treatment period when administered on an as-needed basis in the home setting.
• Adverse event frequencies with a single dose were similar to those observed under medical supervision in previously completed Phase 3 studies (SERENITY I & II).
• Over repeat dosing, no increase in treatment-emergent adverse events (TEAEs) was observed.
• No patient in the active arm discontinued due to TEAEs.
• Reduction in modified Clinical Global Impression Severity (mCGI-S) score was significantly greater in the active group compared with placebo (P<0.05).
• The reduction in symptoms remained consistent throughout the trial, with no attenuation of benefit with repeat dosing (mean reduction of 1.2 after 1-12 doses and 1.4 after 13+ doses).
• Significantly more patients experienced full resolution of agitation symptoms with BXCL501 than with placebo across agitation episode severity (P<.0001).

Negatives

• The study was primarily a safety study and 'not powered for efficacy,' meaning efficacy results are exploratory and require further confirmation.
• Common TEAEs included somnolence (22.5% for BXCL501 vs 17.0% for placebo on first dose), dry mouth (6.9% vs 0.9%), dizziness (4.9% vs 0.9%), and oral paresthesia/hypoesthesia (2% vs 0.9%) for BXCL501 120 mcg on first dose in the home setting.

Risks

• Potential for adverse events such as somnolence, oral paresthesia/hypoesthesia, dizziness, dry mouth, nausea, and headache, as observed in the study.
• The study was not powered for efficacy, meaning the observed efficacy signals are exploratory and require further confirmation for regulatory approval for efficacy in the home setting.

Future Outlook

The company initiated this Phase 3 safety trial with the goal of expanding the indication of BXCL501 into the unsupervised (home) setting, implying future regulatory submissions for this expanded use.

Management Comments

• "In this pivotal safety study, sublingual dexmedetomidine 120 mcg was safe and well tolerated over a 12-week treatment period when administered on an as-needed basis."
• "Over repeat dosing, no increase in TEAEs was observed."
• "The reduction in symptoms remained consistent throughout the duration of the trial."
• "Significantly more patients experienced full resolution of agitation symptoms with BXCL501 than with placebo."

Industry Context

Agitation associated with schizophrenia and bipolar disorder represents a significant unmet medical need, particularly in the home setting where most episodes occur and there are currently no FDA-approved therapies. BXCL501, if approved for home use, would address a critical gap in treatment options, potentially improving patient quality of life and reducing the burden on healthcare systems.

Comparison to Industry Standards

• Currently, there are no FDA-approved therapies for agitation associated with bipolar disorder or schizophrenia specifically for the home setting, positioning BXCL501 as a potential first-in-class treatment for this indication.
• The safety profile of BXCL501 120 mcg in the home setting was similar to that observed in previous Phase 3 studies (SERENITY I & II) conducted under medical supervision, suggesting a consistent safety profile across different administration environments.

Stakeholder Impact

• Shareholders: Positive impact due to successful Phase 3 safety results and promising exploratory efficacy data, potentially leading to market expansion and increased revenue.
• Patients: Potential for a new, convenient, and effective treatment option for agitation in the home setting, where no FDA-approved therapies currently exist.
• Healthcare Providers: New tool for managing agitation in patients with bipolar disorder or schizophrenia outside of clinical settings.

Next Steps

• The company's goal is to expand the indication of BXCL501 into the unsupervised (home) setting, implying future regulatory submissions based on these and potentially other data.

Key Dates

Recommendation

The successful Phase 3 safety study for BXCL501 in the home setting, coupled with strong exploratory efficacy signals, represents a significant de-risking event and opens up a substantial new market opportunity where there are currently no FDA-approved treatments. This positive clinical data is highly likely to drive future revenue growth and enhance shareholder value, making it a strong buy for investors.

Keywords

BioXcel Therapeutics, BXCL501, Dexmedetomidine, Agitation, Bipolar Disorder, Schizophrenia, Phase 3 Study, Home Setting, Sublingual Film, Clinical Trial, Neuroscience, Psychiatry, FDA Approval